These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34053791)

  • 61. Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines.
    Alipon SB; Takashima Y; Avagyan T; Grabovac V; Aslam SK; Bayutas B; Logronio J; Wang X; Shrestha A; Neupane S; Roces MC; Apostol LN; Sucaldito N
    Western Pac Surveill Response J; 2022; 13(2):1-7. PubMed ID: 36276175
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Polio outbreaks in Namibia, 1993-1995: lessons learned.
    Biellik RJ; Allies T; Woodfill CJ; Lobanov A
    J Infect Dis; 1997 Feb; 175 Suppl 1():S30-6. PubMed ID: 9203689
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Progress Toward Poliomyelitis Eradication - Worldwide, January 2021-March 2023.
    Lee SE; Greene SA; Burns CC; Tallis G; Wassilak SGF; Bolu O
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(19):517-522. PubMed ID: 37167156
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021.
    Yang H; Qi Q; Zhang Y; Wen N; Cao L; Liu Y; Fan C; Yan D; Zhu X; Hao L; Zhu S; Ma Q; Liu J; Ma C; Nan L; Chen Y; Ma X; Chen N; Deng K; Shao G; Ding X; An Z; Rodewald LE; Li X; Wang D; Zhu H; Wang H; Feng Z; Xu W; Zhou J; Yin Z;
    JAMA Netw Open; 2023 Jan; 6(1):e2249710. PubMed ID: 36602797
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates.
    Kroiss SJ; Famulare M; Lyons H; McCarthy KA; Mercer LD; Chabot-Couture G
    Vaccine; 2017 Oct; 35(42):5674-5681. PubMed ID: 28890193
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication.
    Lopalco PL
    Epidemiol Infect; 2017 Feb; 145(3):413-419. PubMed ID: 27866483
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Voorman A; O'Reilly K; Lyons H; Goel AK; Touray K; Okiror S
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A105-A112. PubMed ID: 34483024
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Update on vaccine-derived polioviruses.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(40):1093-7. PubMed ID: 17035927
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Surveillance systems to track progress toward global polio eradication - worldwide, 2012-2013.
    Levitt A; Diop OM; Tangermann RH; Paladin F; Kamgang JB; Burns CC; Chenoweth PJ; Goel A; Wassilak SG;
    MMWR Morb Mortal Wkly Rep; 2014 Apr; 63(16):356-61. PubMed ID: 24759658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identification and control of a poliomyelitis outbreak in Xinjiang, China.
    Luo HM; Zhang Y; Wang XQ; Yu WZ; Wen N; Yan DM; Wang HQ; Wushouer F; Wang HB; Xu AQ; Zheng JS; Li DX; Cui H; Wang JP; Zhu SL; Feng ZJ; Cui FQ; Ning J; Hao LX; Fan CX; Ning GJ; Yu HJ; Wang SW; Liu DW; Wang DY; Fu JP; Gou AL; Zhang GM; Huang GH; Chen YS; Mi SS; Liu YM; Yin DP; Zhu H; Fan XC; Li XL; Ji YX; Li KL; Tang HS; Xu WB; Wang Y; Yang WZ
    N Engl J Med; 2013 Nov; 369(21):1981-90. PubMed ID: 24256377
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Sep; 61():741-6. PubMed ID: 22992572
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
    Thompson KM; Kalkowska DA; Badizadegan K
    Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016.
    Etsano A; Damisa E; Shuaib F; Nganda GW; Enemaku O; Usman S; Adeniji A; Jorba J; Iber J; Ohuabunwo C; Nnadi C; Wiesen E
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(30):770-3. PubMed ID: 27490081
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
    Immunization Systems Management Group of the Global Polio Eradication Initiative
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Surveillance To Track Progress Toward Poliomyelitis Eradication - Worldwide, 2021-2022.
    Stehling-Ariza T; Wilkinson AL; Diop OM; Jorba J; Asghar H; Avagnan T; Grabovac V; Johnson T; Joshi S; Kfutwah AKW; Sangal L; Sharif S; Wahdan A; Tallis GF; Kovacs SD
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(23):613-620. PubMed ID: 37289657
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acute flaccid paralysis surveillance performance from 2011 to 2020 in Jonglei State, South Sudan: progress and challenges encountered.
    Jil JM; Tegegne AA; Maleghemi S; Berta KK; Birru TG; Kilo OTD
    Pan Afr Med J; 2022; 42(Suppl 1):11. PubMed ID: 36158927
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Surveillance to Track Progress Toward Polio Eradication - Worldwide, 2020-2021.
    Wilkinson AL; Diop OM; Jorba J; Gardner T; Snider CJ; Ahmed J
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(15):538-544. PubMed ID: 35421079
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020.
    Chard AN; Martinez M; Matanock A; Kassem AM
    Vaccine; 2021 Oct; 39(42):6250-6255. PubMed ID: 34538696
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Stopping circulatory vaccine-derived poliovirus in Kaduna state by scaling up special interventions in local government areas along rivers of interest- kamacha basin experience, 2013-2015.
    Musa AI; Shuaib F; Braka F; Mkanda P; Banda R; Korir C; Tegegne SG; Abdullahi S; Umeh GC; Nomhwange TI; Iyal HA; Ishaku S; Adamu U; Damisa E; Bagana M; Gugong V; Balarabe H; Nsubuga P; Vaz RG
    BMC Public Health; 2018 Dec; 18(Suppl 4):1303. PubMed ID: 30541497
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.